KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Assets (2017 - 2025)

Novartis Ag's Assets history spans 9 years, with the latest figure at $110.9 billion for Q4 2025.

  • For Q4 2025, Assets rose 8.51% year-over-year to $110.9 billion; the TTM value through Dec 2025 reached $110.9 billion, up 8.51%, while the annual FY2025 figure was $110.9 billion, 8.51% up from the prior year.
  • Assets for Q4 2025 was $110.9 billion at Novartis Ag, up from $102.2 billion in the prior quarter.
  • Across five years, Assets topped out at $131.8 billion in Q4 2021 and bottomed at $99.9 billion in Q4 2023.
  • The 5-year median for Assets is $110.9 billion (2025), against an average of $112.5 billion.
  • The largest annual shift saw Assets dropped 14.91% in 2023 before it increased 8.51% in 2025.
  • A 5-year view of Assets shows it stood at $131.8 billion in 2021, then fell by 10.88% to $117.5 billion in 2022, then fell by 14.91% to $99.9 billion in 2023, then rose by 2.3% to $102.2 billion in 2024, then grew by 8.51% to $110.9 billion in 2025.
  • Per Business Quant, the three most recent readings for NVS's Assets are $110.9 billion (Q4 2025), $102.2 billion (Q4 2024), and $99.9 billion (Q4 2023).